Paclitaxel and Docetaxel combinations in non-small cell lung cancer

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Paclitaxel, the first of the taxanes, has exhibited unique and encouraging single-agent activity in the treatment of non-small cell lung cancer (NSCLC). Yet, with single-agent response rates approaching 25%, it was logical to examine the impact of paclitaxel in combination chemotherapy regimens. In trials evaluating the activity of paclitaxel in combination with one of the platinum compounds, cisplatin or carboplatin, response rates have ranged from 35 to > 50% and were significantly better than response rates observed with etoposide/cisplatin, the previous standard regimen for treatment of NSCLC. Docetaxel is a newer taxane that also has exhibited notable single-agent activity and response rates ranging from 20 to 50% when combined with cisplatin. Future research will look to refine the use of taxane combinations in NSCLC and to examine the potential of these unique and promising drugs when combined with newer agents that are active against this disease.

Original languageEnglish (US)
Pages (from-to)144S-151S
JournalCHEST
Volume117
Issue number4 SUPPL. 1
DOIs
StatePublished - Jan 1 2000

Fingerprint

docetaxel
Paclitaxel
Non-Small Cell Lung Carcinoma
Cisplatin
Platinum Compounds
Taxoids
Carboplatin
Etoposide
Combination Drug Therapy
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{bfbe1c869ece41b8badb912b891f2c06,
title = "Paclitaxel and Docetaxel combinations in non-small cell lung cancer",
abstract = "Paclitaxel, the first of the taxanes, has exhibited unique and encouraging single-agent activity in the treatment of non-small cell lung cancer (NSCLC). Yet, with single-agent response rates approaching 25{\%}, it was logical to examine the impact of paclitaxel in combination chemotherapy regimens. In trials evaluating the activity of paclitaxel in combination with one of the platinum compounds, cisplatin or carboplatin, response rates have ranged from 35 to > 50{\%} and were significantly better than response rates observed with etoposide/cisplatin, the previous standard regimen for treatment of NSCLC. Docetaxel is a newer taxane that also has exhibited notable single-agent activity and response rates ranging from 20 to 50{\%} when combined with cisplatin. Future research will look to refine the use of taxane combinations in NSCLC and to examine the potential of these unique and promising drugs when combined with newer agents that are active against this disease.",
author = "Belani, {Chandra P.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1378/chest.117.4_suppl_1.144S",
language = "English (US)",
volume = "117",
pages = "144S--151S",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4 SUPPL. 1",

}

Paclitaxel and Docetaxel combinations in non-small cell lung cancer. / Belani, Chandra P.

In: CHEST, Vol. 117, No. 4 SUPPL. 1, 01.01.2000, p. 144S-151S.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Paclitaxel and Docetaxel combinations in non-small cell lung cancer

AU - Belani, Chandra P.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Paclitaxel, the first of the taxanes, has exhibited unique and encouraging single-agent activity in the treatment of non-small cell lung cancer (NSCLC). Yet, with single-agent response rates approaching 25%, it was logical to examine the impact of paclitaxel in combination chemotherapy regimens. In trials evaluating the activity of paclitaxel in combination with one of the platinum compounds, cisplatin or carboplatin, response rates have ranged from 35 to > 50% and were significantly better than response rates observed with etoposide/cisplatin, the previous standard regimen for treatment of NSCLC. Docetaxel is a newer taxane that also has exhibited notable single-agent activity and response rates ranging from 20 to 50% when combined with cisplatin. Future research will look to refine the use of taxane combinations in NSCLC and to examine the potential of these unique and promising drugs when combined with newer agents that are active against this disease.

AB - Paclitaxel, the first of the taxanes, has exhibited unique and encouraging single-agent activity in the treatment of non-small cell lung cancer (NSCLC). Yet, with single-agent response rates approaching 25%, it was logical to examine the impact of paclitaxel in combination chemotherapy regimens. In trials evaluating the activity of paclitaxel in combination with one of the platinum compounds, cisplatin or carboplatin, response rates have ranged from 35 to > 50% and were significantly better than response rates observed with etoposide/cisplatin, the previous standard regimen for treatment of NSCLC. Docetaxel is a newer taxane that also has exhibited notable single-agent activity and response rates ranging from 20 to 50% when combined with cisplatin. Future research will look to refine the use of taxane combinations in NSCLC and to examine the potential of these unique and promising drugs when combined with newer agents that are active against this disease.

UR - http://www.scopus.com/inward/record.url?scp=0033999225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033999225&partnerID=8YFLogxK

U2 - 10.1378/chest.117.4_suppl_1.144S

DO - 10.1378/chest.117.4_suppl_1.144S

M3 - Article

C2 - 10777470

AN - SCOPUS:0033999225

VL - 117

SP - 144S-151S

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4 SUPPL. 1

ER -